A study on breast cancer conducted at IRB Barcelona identifies the key role of p38 in safeguarding tumour cells against the excessive accumulation of DNA damage, which would otherwise cause cell death.
p38 blockage has been shown to increase the death of tumour cells, thus causing tumours to shrink.
The combination of p38 inhibitors with chemotherapeutic drugs (taxanes) strengthens, accelerates or prolongs the antitumour effect in patient-derived tumours grown in mice.
The study, published in The Journal of Cell Biology, focuses on the development of the sperm tail, the structure that enables sperm cells to swim and is therefore critical for male fertility.
IRB Barcelona scientist, Modesto Orozco has been granted 150,000 euros to optimise and validate a promising anti-tumour therapeutic tool over 18 months.
The Business Advisory Board (BAB) visited IRB Barcelona on 3 April. Launched in 2013 and convening every two years, the BAB puts their expertise to the service of the Institute with the aim to speed up technology transfer and map out a successful tech-transfer roadmap.
During the visit, the BAB advised the Innovation Department on the tech transfer strategy for the next three years and gave specific guidance on how to push those innovation projects that are closest to the market. The board was debriefed on several initiatives in the "tech transfer" field, such as the Entrepreneur in Residence Programme, and had an informal meeting with about 20 pre and postdocs. “This session...
Metastasis refers to the spread of cancer from one place in the body to another. This process causes 90% of deaths from cancer, making it one of the most relevant public health challenges today. Cancer is a disease that affects our entire society, and as such, society as a whole must come together to find the cure. It was under this premise that IRB Barcelona, in collaboration with ESADE Business School, brought together key figures from the research, business and innovation, and private sectors to learn about the state of the art in metastasis research, debate the power that business and innovation hold to accelerate cures, and outline future challenges.
Researchers at IRB Barcelona discover the mechanism that leads to a less harmful form of obesity that is associated with the number rather than volume of fat cells.
There are several types of obesity and some are more harmful than others.
The study has been published in the journal Nature Cell Biology.
A study headed by IRB Barcelona provides the first direct evidence of beta-amyloid dimers (two proteins joined together) in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers.
Beta-amyloid dimers may be the smallest pathological species that trigger Alzheimer’s disease.
The new study analyses the dysfunction of basolateral transporters through a transgenic animal model.
This study is led by Manuel Palacín from IRB Barcelona and Virgínia Nunes from IDIBELL.
Yesterday IRB Barcelona’s Board of Trustees appointed the renowned scientist as director of the Institute, a position that he will take up on 1 May.
Francesc Posas succeeds Joan J. Guinovart, the director and founder of the Institute.
A study performed at IRB Barcelona supports the notion that mitochondrial defects underlie a set of diseases of unknown origin that involve chronic muscle inflammation.